Abstract:Background: Emerging as the most abundant posttranscriptional internal mRNA modification in eukaryotes, N6-methyladenosine (m6A) modification has gathered tremendous scientific interest in recent years. However, no study addresses the role of m6A modification in ferroptosis. Here, we showed that m6A modifications are decreased in RSL3-induced ferroptosis in hypopharyngeal squamous cell carcinoma (HPSCC). We found that AlkB homolog 5 (ALKBH5), one of the m6A demethylases, is the primary factor involved in aberrant m6A modification. Methods: Bioinformatics analysis, sample analysis, cell biological analyses and transcriptome sequencing were performed to evaluate the correlation between m6A modification and ferroptosis as well as molecular mechanism of ALKBH5 function. Transcriptome-wide m6A-seq and RIP-seq data and following m6A dot blot, MeRIP-qPCR, RIP-qPCR and dual luciferase reporter assays were mapped to screen and validate the candidate targets of ALKBH5.Results: ALKBH5-knockdown impaired ferroptotic cell death in HPSCC. However, overexpression of ALKBH5 has an opposite effect, suggesting that ALKBH5 is a positive regulator of ferroptosis. Mechanistically, ALKBH5-mediated m6A demethylation led to a post-transcriptional inhibition of NFE2L2/NRF2, the central player in the regulation of antioxidant molecules in cells, at two m6A residues in the 3ʹ-UTR. Therefore, knocking down ALKBH5 subsequently increases the expression levels of NFE2L2/NRF2 and increased cell resistance to ferroptosis. In addition, m6A -mediated NFE2L2/NRF2 stabilization relied on the m6A reader IGF2BP2.Conclusion: ALKBH5 functions as a tumor suppresser through ferroptosis in HPSCC. ALKBH5 destabilizes NFE2L2/NRF2 expression in HPSCC through an m6A-IGF2BP2-dependent mechanism. Together, our work uncovers a critical link between ALKBH5-NFE2L2/NRF2 and ferroptosis, providing insight into the functional importance of the reversible mRNA m6A methylation and its modulators in HPSCC.Funding Information: This work was supported by the Natural Science Foundation of Zhejiang Province (No. LY21H160031), National Natural Science Foundation of China (No. 62071415, No.81903160), Medical Health Science and Technology Project of Zhejiang Provincial Health Commission Grants (No. 2019336033 and No. 2020367813).Declaration of Interests: The authors declare that they have no competing interests.Ethics Approval Statement: According to the protocol approved by the Ethical Review Committee of the Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University. Patient tissue samples were obtained with informed consent. The in vivo assay using nude mice was approved by the Ethics Review Committee of Zhejiang University college of Medicine. All animal studies were carried out in accordance with Institute of Laboratory Animal Resources guidelines and approved by the University Committee on the Use and Care of Animals at the Zhejiang University.

High expression of AlkB homolog 5 suppresses the progression of non‐small cell lung cancer by facilitating ferroptosis through m6A demethylation of SLC7A11

ALKBH5 decreases SLC7A11 expression by erasing m6A modification and promotes the ferroptosis of colorectal cancer cells

M(6)a Mrna Methylation Regulates Ferroptosis in HPSCC by Targeting NFE2L2/NRF2

Suppression of m6A mRNA modification by DNA hypermethylated ALKBH5 aggravates the oncological behavior of KRAS mutation/LKB1 loss lung cancer

ALOX5 Deficiency Contributes to Bladder Cancer Progression by Mediating Ferroptosis Escape

ALKBH5 suppresses malignancy of hepatocellular carcinoma via m6A-guided epigenetic inhibition of LYPD1

Ferroptosis-associated gene SLC7A11 is upregulated in NSCLC and correlated with patient’s poor prognosis: An integrated bioinformatics analysis

RNA Demethylase ALKBH5 Prevents Lung Cancer Progression by Regulating EMT and Stemness via Regulating p53

ALKBH5 promotes non-small cell lung cancer progression and susceptibility to anti-PD-L1 therapy by modulating interactions between tumor and macrophages

The N6‐methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma

ALKBH1 promotes lung cancer by regulating m6A RNA demethylation

USP5 Stabilizes IKBKG Through Deubiquitination to Suppress Ferroptosis and Promote Growth in Non-small Cell Lung Cancer

METTL3-mediated m6A modification enhances ZDHHC16 expression in nonsmall- cell lung cancer patients, attenuating ferroptosis by suppressing CREB ubiquitination

AhR Promotes the Development of Non-small cell lung cancer by Inducing SLC7A11-dependent Antioxidant Function

HDAC10 inhibits non-small-cell lung cancer cell ferroptosis through the microRNA-223-5p-SLC7A11 axis

ALKBH5 inhibits thyroid cancer progression by promoting ferroptosis through TIAM1–Nrf2/HO-1 axis

RNA demethylase ALKBH5 suppresses tumorigenesis via inhibiting proliferation and invasion and promoting CD8 + T cell infiltration in colorectal cancer

ALKBH5 promotes the development of lung adenocarcinoma by regulating the polarization of M2 macrophages through CDCA4

m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2–mediated YAP activity in NSCLC

ALKBH5 Modulates Asthma Progression by Downregulating N6-methyladenosine Methylation

RNA Demethylase ALKBH5 Inhibits TGF‐β‐induced EMT by Regulating TGF‐β/SMAD Signaling in Non‐small Cell Lung Cancer